Cardiovascular Center, Kitano Hospital, The Tazuke Kofukai Medical Research Institute, Osaka, Japan.
Am J Cardiol. 2011 Jan 15;107(2):168-74. doi: 10.1016/j.amjcard.2010.09.007. Epub 2010 Dec 2.
Whole-body periodic acceleration (WBPA) has been developed as a passive exercise device capable of improving endothelial function by applying pulsatile shear stress to vascular endothelium. We hypothesized that treatment with WBPA improves exercise capacity, myocardial ischemia, and left ventricular (LV) function because of increased coronary and peripheral vasodilatory reserves in patients with angina. Twenty-six patients with angina who were not indicated for percutaneous coronary intervention and/or coronary artery bypass grafting were randomly assigned to remain sedentary (sedentary group) or undergo 20 sessions of WBPA with the motion platform for 4 weeks (WBPA group) in addition to conventional medical treatment. WBPA was applied at 2 to 3 Hz and approximately ±2.2 m/s² for 45 minutes. We repeated the symptom-limited treadmill exercise test and adenosine sestamibi myocardial scintigraphy. In the WBPA group, the exercise time until 0.1-mV ST-segment depression increased by 53% (p <0.01) and the double product at 0.1-mV ST-segment depression by 23% (p <0.001). Severity score of myocardial scintigraphy during adenosine infusion decreased from 20 ± 10 to 14 ± 8 (p <0.001) and severity score at rest also decreased from 13 ± 10 to 8 ± 10 (p <0.01). On scintigraphic images at rest, LV end-diastolic volume index decreased by 18% (p <0.01) with an augmentation of LV ejection fraction from 50 ± 16% to 55 ± 16% (p <0.01). In contrast, all studied parameters remained unchanged in the sedentary group. In conclusion, treatment with WBPA for patients with angina ameliorates exercise capacity, myocardial ischemia, and LV function.
全身周期性加速(WBPA)已被开发为一种被动运动设备,通过向血管内皮施加脉动剪切力来改善内皮功能。我们假设,由于心绞痛患者的冠状动脉和外周血管舒张储备增加,全身周期性加速治疗可以改善运动能力、心肌缺血和左心室(LV)功能。
26 名不适合经皮冠状动脉介入治疗和/或冠状动脉旁路移植术的心绞痛患者被随机分为两组:静息组( sedentary 组)和接受全身周期性加速治疗组( WBPA 组),除了常规的药物治疗外,两组患者均接受为期 4 周、每天 20 次的全身周期性加速治疗,运动平台频率为 2 至 3Hz,加速度约为±2.2m/s²,每次 45 分钟。我们重复了症状限制的跑步机运动试验和腺苷 sestamibi 心肌闪烁显像。在 WBPA 组中,0.1mVST 段压低时的运动时间增加了 53%(p <0.01),0.1mVST 段压低时的双乘积增加了 23%(p <0.001)。腺苷输注时心肌闪烁显像的严重程度评分从 20 ± 10 降至 14 ± 8(p <0.001),静息时的严重程度评分也从 13 ± 10 降至 8 ± 10(p <0.01)。在静息时的闪烁显像图像上,LV 舒张末期容积指数降低了 18%(p <0.01),LV 射血分数从 50 ± 16%增加到 55 ± 16%(p <0.01)。相比之下,静息组的所有研究参数均无变化。
总之,全身周期性加速治疗可改善心绞痛患者的运动能力、心肌缺血和 LV 功能。